ArticleBritish journal of cancer2008
Effect of the chemokine receptor CXCR7 on proliferation of carcinoma cells in vitro and in vivo.
Article in British journal of cancer, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- The Role of the CXCL12/CXCR4/CXCR7 Chemokine Axis in Cancer.Frontiers in pharmacology · 2020Review
- Coexpression of CCR7 and CXCR4 During B Cell Development Controls CXCR4 Responsiveness and Bone Marrow Homing.Frontiers in immunology · 2019Article
- Critical involvement of atypical chemokine receptor CXCR7 in allergic airway inflammation.Immunology · 2018Article
- Downregulation of CXCL12 in mesenchymal stromal cells by TGFβ promotes breast cancer metastasis.Oncogene · 2017Article
- SDF-1/CXCR7 axis regulates the proliferation, invasion, adhesion, and angiogenesis of gastric cancer cells.World journal of surgical oncology · 2016Article
- Silencing of CXCR2 and CXCR7 protects against esophageal cancer.American journal of translational research · 2016Article
- Expression and functional roles of the chemokine receptor CXCR7 in acute myeloid leukemia cells.Blood research · 2015Article
- Crosstalk between SDF-1/CXCR4 and SDF-1/CXCR7 in cardiac stem cell migration.Scientific reports · 2015Article
- Chemokine-Derived Peptides: Novel Antimicrobial and Antineoplasic Agents.International journal of molecular sciences · 2015Review
- Expression of stromal cell-derived factor 1 and CXCR7 ligand receptor system in pancreatic adenocarcinoma.World journal of surgical oncology · 2014Article
- Insights on the CXCL12-CXCR4 axis in hepatocellular carcinoma carcinogenesis.American journal of translational research · 2014Review
- CXCR7-mediated progression of osteosarcoma in the lungs.British journal of cancer · 2013Article
- Clinical applications of gene expression in colorectal cancer.Journal of gastrointestinal oncology · 2013Article
- CXCR7 receptors facilitate the progression of colon carcinoma within lung not within liver.British journal of cancer · 2012Article
- Expression of stromal cell-derived factor 1 and CXCR7 in papillary thyroid carcinoma.Endocrine pathology · 2012Article
- Differential effects of CXCR4 antagonists on the survival and proliferation of myeloid leukemia cells in vitro.The Korean journal of hematology · 2011Article
- C-terminal region of EBNA-2 determines the superior transforming ability of type 1 Epstein-Barr virus by enhanced gene regulation of LMP-1 and CXCR7.PLoS pathogens · 2011Article
- The role of CXCR7 on the adhesion, proliferation and angiogenesis of endothelial progenitor cells.Journal of cellular and molecular medicine · 2011Article
- CCL25 mediates migration, invasion and matrix metalloproteinase expression by breast cancer cells in a CCR9-dependent fashion.International journal of oncology · 2011Article
- The expression of CXCR4, CXCL12 and CXCR7 in malignant pleural mesothelioma.The Journal of pathology · 2011Article
Corrections and comments
- Retraction · 2011-01-04Concerns/Issues about Authorship/Affiliation · Investigation by Company/Institution ·
- Retracted
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The chemokine CXCL12/SDF-1 and its receptor CXCR4 have been implicated in invasion, survival and proliferation of carcinoma cells. Recently, CXCR7 was identified as a second receptor for CXCL12. We observed that CXCL12 promoted proliferation of CT26 colon and KEP1 mammary carcinoma cells, and this was blocked when CXCR7 was downregulated by 'intrakines' or RNAi, but not by CXCR4 inhibitors. The K1R mutant of CXCL12, which acts as a CXCR4 antagonist, also promoted proliferation through CXCR7 and is therefore a selective CXCR7 agonist. The effect of CXCR7 was not due to reduced apoptosis, and CXCR7 mediated chemotaxis of the carcinoma cells towards CXCL12. These results differ from those in a previous report on other carcinoma cells. We conclude that CXCL12 can be a potent growth factor for carcinoma cells by acting on CXCR7. Nevertheless, we observed no effect of complete and stable CXCR7 suppression on the growth of s.c. tumours or lung metastases of KEP1 and CT26 cells. A CXCR7 inhibitor has been reported to reduce growth of other tumours. Our results indicate that this inhibitor may not be applicable to therapy of all carcinomas.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.